Drug Profile
Cancer therapeutic - AstraZeneca/Sarah Cannon Research Institute
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator AstraZeneca; Sarah Cannon Research Institute
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in USA
- 23 Nov 2010 Clinical trials in Cancer in USA (unspecified route)